{"filing":{"accession_number":"0001213900-26-082876","cik":"0001795091","ticker":"OSTX","company_name":"OS Therapies Inc","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-23","primary_document":"ea0299692-8k_ostherapies.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026082876/ea0299692-8k_ostherapies.htm"},"events":[{"id":21773,"run_id":19642,"accession_number":"0001213900-26-082876","anchor_item_number":"1.02","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"OS Therapies terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading, eliminating access to $17.5 million in remaining authorized equity issuance capacity. While this is a termination of a material definitive agreement (Item 1.02), the core event is financial—the loss of a capital-raising mechanism—rather than a traditional M\u0026A activity, debt issuance, or other specific financial category. The company had raised only ~$530k of the $18 million authorized, suggesting limited reliance on this facility, but the termination removes future flexibility and is material to investor assessment of the company's capital strategy.","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21489,"accession_number":"0001213900-26-082876","item_number":"1.02","item_title":"Termination of a Material Definitive","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"OS Therapies terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading, eliminating access to $17.5 million in remaining authorized equity issuance capacity. While this is a termination of a material definitive agreement (Item 1.02), the core event is financial—the loss of a capital-raising mechanism—rather than a traditional M\u0026A activity, debt issuance, or other specific financial category. The company had raised only ~$530k of the $18 million authorized, suggesting limited reliance on this facility, but the termination removes future flexibility and is material to investor assessment of the company's capital strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:06.506443+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21489,"accession_number":"0001213900-26-082876","item_number":"1.02","item_title":"Termination of a Material Definitive","event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"OS Therapies terminated its At Market Issuance Sales Agreement with B. Riley Securities and JonesTrading, eliminating access to $17.5 million in remaining authorized equity issuance capacity. While this is a termination of a material definitive agreement (Item 1.02), the core event is financial—the loss of a capital-raising mechanism—rather than a traditional M\u0026A activity, debt issuance, or other specific financial category. The company had raised only ~$530k of the $18 million authorized, suggesting limited reliance on this facility, but the termination removes future flexibility and is material to investor assessment of the company's capital strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T00:17:06.506443+00:00","company_name":"OS Therapies Inc","ticker":"OSTX","filing_date":"2026-07-29"}]}